The goal of this clinical trial is to evaluate the safety and tolerability of a single dose of ER-100 in adults with optic nerve conditions, specifically Open Angle Glaucoma (OAG) and Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION). The main questions it aims to answer are: * Is ER-100 safe when given as a single dose to people with OAG or NAION * What side effects may occur, if any, after taking ER-100? Participants will: * Receive a single dose of ER-100 * Undergo safety assessments including detailed eye examination and laboratory tests * Provide body fluid samples (tears, saliva, feces, urine) to help researchers understand how the drug is processed and cleared from the body * Complete questionnaires about their quality of life * Be followed for up to 5 years to monitor long-term health and vision outcomes
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Incidence of Treatment-Emergent Adverse Events (TEAEs) During and Post-Doxycycline Activation Period
Timeframe: Baseline to Day 56, Day 112
Incidence of Dose-Limiting Toxicities During and Post-Doxycycline Activation Period
Timeframe: Baseline to Day 56, Day 112
Change in Safety Laboratory Tests (Liver Function Tests - LFTs) During and Post-Doxycycline Activation Period
Timeframe: Baseline to Day 56, Day 112
Change in Safety Laboratory Tests (Blood Protein Levels) During and Post-Doxycycline Activation Period
Timeframe: Baseline to Day 56, Day 112
Change in Safety Laboratory Tests (Calcium, Glucose, Bilirubin, Creatinine, Blood Urea Nitrogen) During and Post-Doxycycline Activation Period
Timeframe: Baseline to Day 56, Day 112
Change in Safety Laboratory Tests (Electrolytes: Sodium, Potassium, Chloride) During and Post-Doxycycline Activation Period
Timeframe: Baseline to Day 56, Day 112
Change in Safety Laboratory Tests (Electrolytes: Bicarbonate and Magnesium) During and Post-Doxycycline Activation Period
Timeframe: Baseline to Day 56, Day 112
Change in Safety Laboratory Tests (Hemoglobin) During and Post-Doxycycline Activation Period
Timeframe: Baseline to Day 56, Day 112
Change in Safety Laboratory Tests (Hematocrit) During and Post-Doxycycline Activation Period
Timeframe: Baseline to Day 56, Day 112
Change in Safety Laboratory Tests (White Blood Cell and Platelet Counts) During and Post-Doxycycline Activation Period
Timeframe: Baseline to Day 56, Day 112
Change in Safety Laboratory Tests (Red Blood Cell Count) During and Post-Doxycycline Activation Period
Timeframe: Baseline to Day 56, Day 112
Change in Safety Laboratory Tests (Erythrocyte Sedimentation Rate) During and Post-Doxycycline Activation Period
Timeframe: Baseline to Day 56, Day 112
Change in Safety Laboratory Tests (C-Reactive Protein) During and Post-Doxycycline Activation Period
Timeframe: Baseline to Day 56, Day 112
Change in Safety Laboratory Tests (Urine Test Results) During and Post-Doxycycline Activation Period
Timeframe: Baseline to Day 56, Day 112
Change from Baseline in the Intraocular Pressure (IOP) in the Treated Eye During and Post-Doxycycline Activation Period - Safety
Timeframe: Baseline to Day 56, Day 112
Change from Baseline in the Best Corrected Visual Acuity (BCVA) Letter Score in the Treated Eye During and Post-Doxycycline Activation Period - Safety
Timeframe: Baseline to Day 56, Day 112
Change from Baseline in Humphrey Visual Field (HVF) Test Results During and Post-Doxycycline Activation Period - Safety
Timeframe: Baseline to Day 56, Day 112
Change from Baseline in Pattern Electroretinogram (pERG) During and Post-Doxycycline Activation Period - Safety
Timeframe: Baseline to Day 56, Day 112
Change from Baseline in Quantitative Contrast Sensitivity Function (qCSF) During and Post-Doxycycline Activation Period - Safety
Timeframe: Baseline to Day 56, Day 112
Change from Baseline in Optical Coherence Tomography (OCT): Ganglion Cell Layer (GCL) Thickness During and Post-Doxycycline Activation Period - Safety
Timeframe: Baseline to Day 56, Day 112
Change from Baseline in Optical Coherence Tomography (OCT): Retinal Nerve Fiber Layer (RNFL) Thickness During and Post-Doxycycline Activation Period - Safety
Timeframe: Baseline to Day 56, Day 112
Change from Baseline in Slit Lamp Exam Results During and Post-Doxycycline Activation Period - Safety
Timeframe: Baseline to Day 56, Day 112